ucn-1028-c and Substance-Withdrawal-Syndrome

Exposure to drugs of abuse or stress results in adaptation in the brain involving changes in gene expression and transcription factors. Morphine withdrawal modulates gene expression through various second-messenger signal transduction systems. Here, we investigated changes in activation of the transcription factor, cAMP-response element binding protein (CREB), in the hypothalamic paraventricular nucleus (PVN) and the kinases that may mediate the morphine withdrawal-triggered activation of CREB and the response of the hypothalamic-pituitary-adrenocortical (HPA) axis after naloxone-induced morphine withdrawal.. The effects of morphine dependence and withdrawal, phosphorylated CREB (pCREB), corticotrophin-releasing factor (CRF) expression in the PVN and HPA axis activity were measured using immunoblotting, immunohistochemistry and radioimmunoassay in controls and in morphine-dependent rats, withdrawn with naloxone and pretreated with vehicle, calphostin C, chelerythrine (inhibitors of protein kinase C (PKC) or SL-327 [inhibitor of extracellular signal regulated kinase (ERK) kinase]. In addition, changes in PKCα and PKCγ immunoreactivity were measured after 60 min of withdrawal.. In morphine-withdrawn rats, pCREB immunoreactivity was increased within CRF immunoreactive neurons in the PVN and plasma corticosterone levels were raised. SL-327, at doses that reduced the augmented pERK levels in the PVN, did not attenuate the rise in pCREB immunoreactivity or plasma corticosterone secretion. In contrast, PKC inhibition reduced the withdrawal-triggered rise in pCREB, pERK1/2 and corticosterone secretion.. PKC mediated, in part, both CREB activation and the HPA response to morphine withdrawal. The ERK kinase/ERK pathway might not be necessary for either activation of CREB or HPA axis hyperactivity.

Topics: Animals; Benzophenanthridines; Corticotropin-Releasing Hormone; Cyclic AMP Response Element-Binding Protein; Extracellular Signal-Regulated MAP Kinases; Hypothalamo-Hypophyseal System; Male; MAP Kinase Kinase Kinases; Mitogen-Activated Protein Kinase 3; Morphine; Morphine Dependence; Naloxone; Naphthalenes; Paraventricular Hypothalamic Nucleus; Phosphorylation; Pituitary-Adrenal System; Protein Kinase C; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome

The transcription factor cAMP response element binding protein (CREB) has been implicated in the actions of drugs of abuse in several brain areas. However, little is known about CREB regulation in the nucleus tractus solitarius (NTS)-A(2) catecholaminergic cell group, one of the key regions of the brain stress system. Morphine withdrawal modulates gene expression in the NTS through various second-messenger signal transduction systems including activation of extracellular signal-regulated kinases 1/2 (ERK(1/2)) and protein kinase C (PKC). In the current study we used immunoblotting and immunohistochemistry to investigate changes in CREB phosphorylation in the NTS and kinases that may mediate the morphine withdrawal-triggered activation of CREB and hypothalamo-pituitary-adrenocortical (HPA) axis (another stress system circuit) response after naloxone-induced morphine withdrawal. We found an increased phosphorylation of CREB (pCREB) selectively within tyrosine hydroxylase (TH) immunoreactive neurons in the NTS from morphine-withdrawn rats, which parallel elevated corticosterone levels. We also measured expression levels of TH and phosphorylated ERK(1/2) (pERK(1/2)), and found that both are up-regulated following morphine withdrawal. SL327, an inhibitor of ERK activation, at doses which reduced the hyperactive pERK(1/2) levels, did not attenuated the rise in pCREB and TH immunoreactivity or plasma corticosterone secretion during morphine withdrawal, indicating that ERK kinase/ERK pathway was not directly needed for either activation of CREB and TH expression in the NTS or HPA axis hyperactivity. In contrast, PKC inhibitor calphostin C reduced the withdrawal-triggered rise in pCREB, pERK(1/2), TH expression and corticosterone secretion. The results indicate that PKC mediates both CREB activation and HPA response by morphine withdrawal and might suggest that CREB activation in the NTS is related to TH expression associated with morphine withdrawal.

Topics: Animals; Catecholamines; Cyclic AMP Response Element-Binding Protein; Male; Morphine; Naloxone; Naphthalenes; Neurons; Phosphorylation; Protein Kinase C; Rats; Rats, Sprague-Dawley; Solitary Nucleus; Substance Withdrawal Syndrome; Tyrosine 3-Monooxygenase

Our previous studies have shown that morphine withdrawal induced an increase in the expression of protein kinase (PK) A and mitogen-activated extracellular kinase (MAPK) pathways in the heart during morphine withdrawal. The purpose of the present study was to evaluate the interaction between PKA and extracellular signal-regulated kinase (ERK) signaling pathways mediating the cardiac adaptive changes observed after naloxone administration to morphine-dependent rats. Dependence on morphine was induced by a 7-day subcutaneous implantation of morphine pellets. Morphine withdrawal was precipitated on day 8 by an injection of naloxone (2 mg/kg). ERK1/2 and tyrosine hydroxylase (TH) phosphorylation was determined by quantitative blot immunolabeling using phosphorylation state-specific antibodies. Naloxone-induced morphine withdrawal activates ERK1/2 and phosphorylates TH at Ser31 in the right and left ventricle, with an increase in the mean arterial blood pressure and heart rate. When N-(2-guanidinoethyl)-5-isoquinolinesulfonamide (HA-1004), a PKA inhibitor, was infused, concomitantly with morphine, it diminished the expression of ERK1/2. In contrast, the infusion of calphostin C (a PKC inhibitor) did not modify the morphine withdrawal-induced activation of ERK1/2. The ability of morphine withdrawal to activate ERK that phosphorylates TH at Ser31 was reduced by HA-1004. The present findings demonstrate that the enhancement of ERK1/2 expression and the phosphorylation state of TH at Ser31 during morphine withdrawal are dependent on PKA and suggest cross-talk between PKA and ERK1/2 transduction pathway mediating morphine withdrawal-induced activation (phosphorylation) of TH.

Topics: Adaptation, Physiological; Aminoacetonitrile; Analgesics, Opioid; Animals; Blotting, Western; Cyclic AMP-Dependent Protein Kinases; Enzyme Inhibitors; Heart; Hemodynamics; Isoquinolines; Male; Mitogen-Activated Protein Kinases; Morphine; Naloxone; Naphthalenes; Narcotic Antagonists; Phosphorylation; Protein Kinase C; Rats; Rats, Sprague-Dawley; Signal Transduction; Substance Withdrawal Syndrome; Sulfonamides; Tyrosine 3-Monooxygenase; Weight Gain

Our previous studies have shown that morphine withdrawal induced hyperactivity of cardiac noradrenergic pathways. The purpose of the present study was to evaluate the effects of morphine withdrawal on site-specific phosphorylation of TH in the heart.. Dependence on morphine was induced by a 7-day s.c. implantation of morphine pellets in rats. Morphine withdrawal was precipitated on day 8 by an injection of naloxone (2 mg kg(-1)). TH phosphorylation was determined by quantitative blot immunolabelling using phosphorylation state-specific antibodies.. Naloxone-induced morphine withdrawal induced phosphorylation of TH at serine (Ser)40 and Ser31 in the right ventricle, associated with both an increase in total TH levels and an enhancement of TH activity. When HA-1004 (PK A inhibitor) was infused, concomitantly with morphine, it diminished the increase in noradrenaline turnover, total TH levels and TH phosphorylation at Ser40 in morphine-withdrawn rats. In contrast, the infusion of calphostin C (PKC inhibitor), did not modify the morphine withdrawal-induced increase in noradrenaline turnover and total TH levels. In addition, we show that the ability of morphine withdrawal to stimulate phosphorylation at Ser31 was reduced by SL327, an inhibitor of ERK 1/2 activation.. The present findings demonstrate that the enhancement of total TH levels and the increased phosphorylation state of TH during morphine withdrawal were dependent on PKA and ERK activities and suggest that these transduction pathways might contribute to the activation of the cardiac catecholaminergic neurons in response to morphine withdrawal.

Topics: Aminoacetonitrile; Animals; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Drug Implants; Isoquinolines; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Morphine; Morphine Dependence; Myocardium; Naloxone; Naphthalenes; Narcotic Antagonists; Norepinephrine; Phosphorylation; Protein Kinase C-delta; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Serine; Substance Withdrawal Syndrome; Sulfonamides; Tyrosine 3-Monooxygenase

We previously demonstrated that morphine withdrawal induced hyperactivity of the heart by activation of noradrenergic pathways innervating the left and right ventricle, as evaluated by noradrenaline (NA) turnover and Fos expression. The present study was designed to investigate the role of protein kinase C (PKC) in this process, by estimating whether pharmacological inhibition of PKC would attenuate morphine withdrawal induced Fos expression and changes in tyrosine hydroxylase (TH) immunoreactivity levels and NA turnover in the left and right ventricle. Dependence on morphine was induced on day 8 by an injection of naloxone. Morphine withdrawal induced Fos expression and increased TH levels and NA turnover in the right and left ventricle. Infusion of calphostin C, a selective PKC inhibitor, did not modify the morphine withdrawal-induced increase in NA turnover and TH levels. However, this inhibitor produced a reduction in the morphine withdrawal-induced Fos expression. The results of the present study provide new information on the mechanisms that underlie morphine withdrawal-induced up-regulation of Fos expression in the heart and suggest that TH is not a target of PKC during morphine withdrawal at heart levels.

Topics: Animals; Heart Ventricles; Male; Morphine; Myocardium; Naloxone; Naphthalenes; Narcotic Antagonists; Norepinephrine; Protein Kinase C; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome; Tyrosine 3-Monooxygenase

Our previous studies have shown an enhanced activity of the noradrenergic system in the heart in rats withdrawn from morphine. In the current study, we examined the role of protein kinase A, protein kinase C and Ca(2+) entry through L-type Ca(2+) channels in naloxone-precipitated increase turnover of noradrenaline in the right and left ventricle. Chronic pretreatment for 7 days with the selective protein kinase A inhibitor, HA-1004 (N-(2' guanidinoethyl)-5-isoquinolinesulfonamide) concomitantly with morphine significantly antagonized the increase in normetanephrine/noradrenaline ratio (an index of noradrenaline turnover) observed in morphine withdrawn rats. However, the infusion of calphostin C (2-(12-(2-(benzoyloxy)propyl)-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxo-1-perylenyl)-1 methylethy carbonic acid 4-hydroxyphenyl ester, a selective protein kinase C inhibitor) did not modify the morphine withdrawal-induced increase in noradrenaline turnover. In addition, when the selective L-type Ca(2+) channel antagonist, nimodipine, was infused it diminished the increased in noradrenaline turnover observed after naloxone administration to morphine dependent rats. Taken together, these data might indicate that protein kinase A activity is necessary for the enhancement of noradrenaline turnover during morphine withdrawal and that an up-regulated Ca(2+) system might contribute to the increase of noradrenaline turnover. The present finding suggests that protein kinase A and Ca(2+) influx through L-type Ca(2+) channels might contribute to the activation of noradrenergic system in the heart observed during morphine withdrawal.

Topics: Animals; Calcium Channels, L-Type; Calcium Signaling; Cyclic AMP-Dependent Protein Kinases; Drug Combinations; Drug Implants; Heart; Infusion Pumps, Implantable; Injections, Subcutaneous; Isoquinolines; Male; Morphine; Morphine Dependence; Naloxone; Naphthalenes; Nimodipine; Norepinephrine; Normetanephrine; Protein Kinase C; Rats; Rats, Sprague-Dawley; Signal Transduction; Substance Withdrawal Syndrome; Sulfonamides; Up-Regulation

Our previous studies have shown an enhanced activity of the hypothalamus-pituitary-adrenocortical axis response in rats withdrawn from morphine, which results from an increase in the hypothalamic paraventricular nucleus noradrenergic activity that is dependent on alpha-adrenoceptor activation. The first objective of this work was to examine the effect of protein kinase A (PKA) and protein kinase C (PKC) inhibitors on morphine withdrawal-induced changes in corticosterone release (an index of the hypothalamus-pituitary-adrenocortical axis activity) and in catecholaminergic turnover in the paraventricular nucleus. Plasma corticosterone levels as well as the concentration of noradrenaline, 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG), dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) in the paraventricular nucleus were determined. The second purpose of the study was to assess whether kinase inhibitors, administered continuously through s.c. osmotic minipumps, get into the brain. Chronic pretreatment for 7 days with the selective PKA inhibitor N-(2'guanidinoethyl)-5-isoquinolinesulfonamide (HA-1004) concomitantly with morphine did not affect the increase in corticosterone release observed after naloxone-precipitated morphine withdrawal. However, pretreatment with the selective PKC inhibitor, calphostin-C significantly antagonized the corticosterone hypersecretion in morphine-withdrawn rats. Neither HA-1004 nor calphostin-C co-administered with morphine for 7 days did modify the morphine withdrawal-induced increase in noradrenaline turnover. Pretreatment with HA-1004 inhibits the increase in dopamine turnover during morphine withdrawal, whereas calphostin-C did not affect the DOPAC/dopamine ratio. Our results might indicate that expression of morphine dependence for hypothalamus-pituitary-adrenocortical axis hyperactivity involves PKC but not PKA signaling mechanisms. It is suggested that in rats PKC may be up-regulated during morphine dependence. High-performance liquid chromatography (HPLC) analysis of hypothalamic tissue from rats perfused with kinase inhibitors demonstrates that both calphostin-C and HA-1004 can cross the blood-brain barrier when administered peripherally.

Topics: 3,4-Dihydroxyphenylacetic Acid; Analgesics, Opioid; Animals; Blood-Brain Barrier; Catecholamines; Chromatography, High Pressure Liquid; Corticosterone; Cyclic AMP-Dependent Protein Kinases; Enzyme Inhibitors; Hypothalamo-Hypophyseal System; Isoquinolines; Male; Methoxyhydroxyphenylglycol; Morphine; Naphthalenes; Norepinephrine; Paraventricular Hypothalamic Nucleus; Pituitary-Adrenal System; Protein Kinase C; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome; Sulfonamides

The involvement of cyclic AMP-dependent protein kinase (PKA) and protein kinase C (PKC) in the modulation of naloxone-precipitated withdrawal jumping in morphine-dependent mice by diabetes was examined. Naloxone-precipitated withdrawal jumps were significantly less in morphine-dependent diabetic mice than in morphine-dependent non-diabetic mice. I.c.v. pretreatment with either calphostin C, a PKC inhibitor, or KT-5720, a PKA inhibitor, attenuated naloxone-precipitated withdrawal jumps in morphine-dependent non-diabetic mice. However, naloxone-precipitated withdrawal jumps in morphine-dependent diabetic mice were not attenuated by i.c.v. pretreatment with either calphostin C or KT5720. Moreover, i.c.v. pretreatment with phorbol-12,13-dibutyrate (PDBu), a PKC activator, attenuated naloxone-precipitated withdrawal jumps in morphine-dependent non-diabetic mice, but not in morphine-dependent diabetic mice. The noradrenaline (NA) turnover in the frontal cortex in morphine-dependent non-diabetic mice, but not in morphine-dependent diabetic mice, was significantly increased 5 min after administration of naloxone. Naloxone-induced enhancement of NA turnover in morphine-dependent non-diabetic mice, but not in morphine-dependent diabetic mice, was blocked by i.c.v. pretreatment with either calphostin C or KT5720 1 hr before naloxone challenge and blocked by PDBu 1 hr before the last injection of morphine. These results suggest that the co-activation of PKC and PKA is needed to elicit naloxone-precipitated withdrawal jumps and enhancement of turnover rate of NA in the frontal cortex in morphine-dependent non-diabetic mice. Furthermore, the attenuation of naloxone-precipitated withdrawal jumps in morphine-dependent diabetic mice may be due, in part, to the desensitization of mu-opioid receptors by the activation of PKC.

Topics: Animals; Behavior, Animal; Carbazoles; Carcinogens; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Experimental; Enzyme Inhibitors; Frontal Lobe; Indoles; Male; Mice; Mice, Inbred ICR; Morphine; Morphine Dependence; Naloxone; Naphthalenes; Narcotic Antagonists; Narcotics; Norepinephrine; Phorbol 12,13-Dibutyrate; Protein Kinase C; Pyrroles; Substance Withdrawal Syndrome